This study is looking at how anti-PD-1 immunotherapy, a type of cancer treatment, might affect your bone mineral density (bone strength). We know that these treatments, while very helpful for many cancers, can sometimes cause side effects in different parts of the body. This study will use special scans called DXA (Dual-Energy X-ray Absorptiometry) and HRpQCT (High Resolution peripheral Quantitative Computed Tomography) to measure your bone density. You could be eligible if you are 18 or older and are starting or have recently started anti-PD-1 immunotherapy for certain cancers, including Triple Negative Breast Cancer, Kidney Cancer, Melanoma, Non-Small Cell Lung Cancer, or MSI-H/dMMR Rectal Cancer. The main goal is to see how much your bone density changes after 12 months of immunotherapy. The current status of this study is unclear, and it plans to enroll 25 participants.

Study design

This is an interventional study, meaning participants will receive specific tests. It plans to enroll 25 participants.

What's involved

You would undergo DXA and HRpQCT scans at the start of immunotherapy, again 4-6 months later, and a final time after 12 months of immunotherapy.

Compensation

Not stated in the trial record.

Follow-up

Bone mineral density will be measured at 12 months after starting immunotherapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.